ATE415957T1 - Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie - Google Patents

Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie

Info

Publication number
ATE415957T1
ATE415957T1 AT04726526T AT04726526T ATE415957T1 AT E415957 T1 ATE415957 T1 AT E415957T1 AT 04726526 T AT04726526 T AT 04726526T AT 04726526 T AT04726526 T AT 04726526T AT E415957 T1 ATE415957 T1 AT E415957T1
Authority
AT
Austria
Prior art keywords
treat epilepsy
adrenoreceptor antagonists
alpha2
alpha2 adrenoreceptor
epilepsy
Prior art date
Application number
AT04726526T
Other languages
English (en)
Inventor
Antti Haapalinna
Asla Pitkaenen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of ATE415957T1 publication Critical patent/ATE415957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04726526T 2003-04-10 2004-04-08 Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie ATE415957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46141303P 2003-04-10 2003-04-10

Publications (1)

Publication Number Publication Date
ATE415957T1 true ATE415957T1 (de) 2008-12-15

Family

ID=33159824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04726526T ATE415957T1 (de) 2003-04-10 2004-04-08 Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie

Country Status (8)

Country Link
US (1) US20080207719A1 (de)
EP (1) EP1610771B1 (de)
JP (1) JP4693769B2 (de)
AT (1) ATE415957T1 (de)
CA (1) CA2521656A1 (de)
DE (1) DE602004018121D1 (de)
ES (1) ES2316977T3 (de)
WO (1) WO2004089349A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016104367A1 (ja) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ 機能性ディスペプシア治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
ATE521593T1 (de) * 2002-04-03 2011-09-15 Orion Corp Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen

Also Published As

Publication number Publication date
EP1610771B1 (de) 2008-12-03
ES2316977T3 (es) 2009-04-16
US20080207719A1 (en) 2008-08-28
EP1610771A2 (de) 2006-01-04
WO2004089349A2 (en) 2004-10-21
JP2006522777A (ja) 2006-10-05
JP4693769B2 (ja) 2011-06-01
WO2004089349A3 (en) 2004-12-09
CA2521656A1 (en) 2004-10-21
DE602004018121D1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DE60321130D1 (de) Variation von parametern zur neurostimulation
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE501125T1 (de) Verfahren zur herstellung des calciumsalzes von rosuvastatin
ATE377004T1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004012079D1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
DE602004020674D1 (de) 1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
EP1337275A4 (de) Verfahren zur verbesserung der wirksamkeit von zytotoxischen mitteln durch verwendung von hsp90-hemmern
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
DE112004001806D2 (de) Verfahren zur Selbstjustierenden Verkleinerung von Strukturen
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
ATE384140T1 (de) Verfahren zur verbesserung der effizienz der tierzüchtung
ATE478661T1 (de) Verfahren zur reduzierung der angiogenese
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE518867T1 (de) Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties